Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

SHSE:688505 Stock Report

Market Cap: CN¥6.5b

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Management

Management criteria checks 1/4

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's CEO is Da Jun Zhao, appointed in May 2023, has a tenure of 1.58 years. total yearly compensation is CN¥1.88M, comprised of 89.9% salary and 10.1% bonuses, including company stock and options. directly owns 1.51% of the company’s shares, worth CN¥98.61M. The average tenure of the management team and the board of directors is 1.6 years and 1.6 years respectively.

Key information

Da Jun Zhao

Chief executive officer

CN¥1.9m

Total compensation

CEO salary percentage89.9%
CEO tenure1.6yrs
CEO ownership1.5%
Management average tenure1.6yrs
Board average tenure1.6yrs

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Da Jun Zhao's remuneration changed compared to Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

CN¥105m

Jun 30 2024n/an/a

CN¥111m

Mar 31 2024n/an/a

CN¥102m

Dec 31 2023CN¥2mCN¥2m

CN¥109m

Sep 30 2023n/an/a

CN¥191m

Jun 30 2023n/an/a

CN¥242m

Mar 31 2023n/an/a

CN¥142m

Dec 31 2022CN¥3mCN¥2m

CN¥138m

Sep 30 2022n/an/a

CN¥132m

Jun 30 2022n/an/a

CN¥112m

Mar 31 2022n/an/a

CN¥213m

Dec 31 2021CN¥5mCN¥2m

CN¥213m

Sep 30 2021n/an/a

CN¥198m

Jun 30 2021n/an/a

CN¥201m

Mar 31 2021n/an/a

CN¥188m

Dec 31 2020CN¥3mCN¥1m

CN¥165m

Sep 30 2020n/an/a

CN¥191m

Jun 30 2020n/an/a

CN¥165m

Mar 31 2020n/an/a

CN¥204m

Dec 31 2019CN¥3mCN¥1m

CN¥227m

Sep 30 2019n/an/a

CN¥151m

Jun 30 2019n/an/a

CN¥151m

Mar 31 2019n/an/a

CN¥91m

Dec 31 2018CN¥2mCN¥1m

CN¥112m

Sep 30 2018n/an/a

CN¥95m

Jun 30 2018n/an/a

CN¥78m

Mar 31 2018n/an/a

CN¥77m

Dec 31 2017CN¥1mCN¥1m

CN¥75m

Compensation vs Market: Da Jun's total compensation ($USD257.97K) is above average for companies of similar size in the CN market ($USD132.14K).

Compensation vs Earnings: Da Jun's compensation has been consistent with company performance over the past year.

CEO

Da Jun Zhao (54 yo)

1.6yrs

Tenure

CN¥1,882,870

Compensation

Mr. Da Jun Zhao has been an Executive Director at Taizhou SPH Pharmaceutical Co., Ltd. since January 2002. Mr. Zhao Co-Founded Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.in November 1996 and ser...

Leadership Team

NamePositionTenureCompensationOwnership
Da Jun Zhao
Co-Founder1.6yrsCN¥1.88m1.51%
CN¥ 98.6m
Xue Yan
CFO, Deputy GM14.3yrsCN¥1.18m0.20%
CN¥ 12.8m
Jun Li
Co-Founder & Deputy GM28.1yrsCN¥2.22m0.87%
CN¥ 56.9m
Luo Chun Wang
Core Technical Personnelno datano data0.11%
CN¥ 7.4m
Dai Qing Yu
Deputy General Manager1.6yrsno data0.064%
CN¥ 4.2m
Yu Chen
Deputy General Manager1.6yrsno data0.018%
CN¥ 1.2m
Xiaowen Li
Deputy General Manager1.6yrsno data0.020%
CN¥ 1.3m

1.6yrs

Average Tenure

53yo

Average Age

Experienced Management: 688505's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Da Jun Zhao
Co-Founder22.9yrsCN¥1.88m1.51%
CN¥ 98.6m
Xue Yan
CFO, Deputy GM1.6yrsCN¥1.18m0.20%
CN¥ 12.8m
Xiao Yang Yu
Non-Executive Director11.6yrsno datano data
Ai Guo Zhou
Supervisor1.6yrsno datano data
Bo Shen
Non Executive Director12.5yrsno datano data
Jian Huang
Independent Chairman of Supervisory Board7.5yrsno datano data
Hong Guang Wang
Independent Non-Executive Director1.6yrsCN¥116.67kno data
Siu Wing Lam
Independent Non-Executive Director1.6yrsno datano data
Pei Long Xu
Independent Non-Executive Director1.6yrsCN¥116.67kno data
Ya Nan Qu
Employee Representative Supervisor1.6yrsno data0.0038%
CN¥ 246.0k

1.6yrs

Average Tenure

54yo

Average Age

Experienced Board: 688505's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 11:06
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack HuDeutsche Bank
Feng Qiang SunGuotai Junan International Holdings Limited
Xiang JunIndustrial Securities Co. Ltd.